Status:

COMPLETED

Explore the Effect of Diet Intervention on Lipid Metabolism and Body Mass Index Among the Patients With Metabolic Syndrome

Lead Sponsor:

First Affiliated Hospital Xi'an Jiaotong University

Collaborating Sponsors:

The Hospital for Sick Children

Leiden University

Conditions:

Metabolic Syndrome

Eligibility:

All Genders

18-65 years

Phase:

NA

Brief Summary

The prevalence of metabolic syndrome (MetS) is increasing all over the world, which is largely related to the increasing obesity population and the current inactive lifestyle of human beings. It is a ...

Eligibility Criteria

Inclusion

  • Inclusion criteria
  • Diagnosed with metabolic syndrome (i.e., more than 3 abnormal findings out of 5):
  • Waist circumference ≥ 90 cm (men) or ≥ 80 cm (women).
  • Elevated TG (use of medications for elevated TG is an alternate indicator) ≥ 150 mg/dL (1.7 mmol/L).
  • Reduced HDL-c (use of medications for reduced HDL-c is an alternate indicator) \< 40 mg/dL (1.0 mmol/L) in males \< 50 mg/dL (1.3 mmol/L) in females.
  • Elevated blood pressure (use of hypoglycemic medications is an alternate indicator). SBP ≥ 130 and/or DBP ≥ 85 mmHg.
  • Elevated FBG (used of hypoglycemic medications is an alternate indicator) ≥ 100 mg/dL (5.6 mmol/L).
  • Age from 18 to 65 years.
  • Stable weight (change ≤ 10% current body weight) for 3 months prior to the study.
  • If participates were on hypoglycemic medications, hypotensive medications, lipid-lowering medications and cardiovascular medications, dose adjustment was not permitted during the 3-month intervention.
  • Exclusion criteria
  • Pregnant or breast-feeding.
  • Night shift workers.
  • History of major diseases or related diseases, such as inflammatory disease, rheumatologic disease, adrenal disease, malignancy, type 1 diabetes, cirrhosis, chronic kidney disease, acquired immunodeficiency syndrome, eating disorder, uncontrolled psychiatric disorder and major adverse cardiovascular event.
  • Current participate in other weight-management program, current on a prescribed diet for special disease or current on any drugs that effect appetite.
  • History of weight-loss surgery.

Exclusion

    Key Trial Info

    Start Date :

    July 12 2020

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    June 30 2022

    Estimated Enrollment :

    169 Patients enrolled

    Trial Details

    Trial ID

    NCT04475822

    Start Date

    July 12 2020

    End Date

    June 30 2022

    Last Update

    July 11 2022

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    First Affiliated Hospital of Xi an Jiaotong University

    Xi'an, Shaanxi, China, 710061